These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27742072)

  • 1. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge.
    Kharfan-Dabaja MA; El-Asmar J; Awan FT; Hamadani M; Ayala E
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):54-66. PubMed ID: 27742072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
    Rafei H; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):1-12. PubMed ID: 28549767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How I treat chronic lymphocytic leukemia after venetoclax.
    Lew TE; Tam CS; Seymour JF
    Blood; 2021 Aug; 138(5):361-369. PubMed ID: 33876212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients.
    Davis JE; Du K; Ludford-Menting MJ; Prabahran A; Wong E; Huntington ND; Koldej RM; Ritchie DS
    Front Immunol; 2021; 12():749094. PubMed ID: 34630428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Shustik C; Bence-Bruckler I; Delage R; Owen CJ; Toze CL; Coutre S
    Ann Hematol; 2017 Jul; 96(7):1185-1196. PubMed ID: 28389687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How should we sequence and combine novel therapies in CLL?
    Davids MS
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
    Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
    Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.
    Jain P; Kanagal-Shamanna R; Konoplev S; Zuo Z; Estrov Z
    Am J Hematol; 2018 Dec; 93(12):1568-1569. PubMed ID: 30152528
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    Brown JR; Hallek MJ; Pagel JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis.
    Kharfan-Dabaja MA; Moukalled N; Reljic T; El-Asmar J; Kumar A
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):53-64. PubMed ID: 29197550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax Yields Strong Responses in CLL.
    Cancer Discov; 2016 Feb; 6(2):113-4. PubMed ID: 26701089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat E; Dreger P
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current strategies to create tailored and risk-adapted therapies for CLL patients.
    Cramer P; Eichhorst B; Reinhardt HC; Hallek M
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):111-121. PubMed ID: 27742065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
    Woyach JA
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):476-481. PubMed ID: 31808904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations.
    Kharfan-Dabaja MA
    Immunotherapy; 2015; 7(1):47-56. PubMed ID: 25572479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
    Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal management of the young patient CLL patient.
    Allan JN; Furman RR
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):73-82. PubMed ID: 29452669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [News in therapeutic management of chronic lymphoid leukemia].
    Michallet AS; Salles G; Coiffier B; Michallet M
    Bull Cancer; 2005 Mar; 92(3):249-56. PubMed ID: 15820919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
    Seymour J
    Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.